An observational study in Obesity & Overweight, sponsored by Yuzuncu Yil University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Yuzuncu Yil University · Observational
This observational study will compare weight loss over two years in adults receiving GLP-1 receptor agonist medications with weight loss in adults who previously underwent laparoscopic sleeve gastrectomy, an operation that reduces the size of the stomach.
Adults starting GLP-1 medications as part of their usual care will be followed for 24 months. Their results will be compared with existing medical records of adults who underwent sleeve gastrectomy at the same center. Treatment decisions will be made by patients and their treating clinicians as part of routine care, rather than assigned by the study.
The main outcome is the percentage of starting body weight lost at 24 months. The study will also assess weight changes at earlier visits, medication side effects, treatment continuation and reasons for stopping treatment, and changes in weight-related health conditions. The groups will be matched using baseline characteristics to make the comparison more balanced.
6,616 studies on the registry are indexed under Obesity; 1,726 are open to participants now.
This study's planned enrollment of 200 is above the median of 134 across 1,347 observational studies indexed under Obesity.
Browse Obesity studies →Yuzuncu Yil University is the lead sponsor of 78 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults aged 18 years or older receiving treatment for obesity or overweight at the Obesity Center of Van Training and Research Hospital, Türkiye. The prospective cohort will include consecutive eligible patients initiating GLP-1 receptor agonist therapy for weight management as part of routine clinical care. The retrospective cohort will include eligible patients who underwent primary laparoscopic sleeve gastrectomy for obesity at the same center between January 1, 2020, and January 1, 2026. Treatment decisions are made independently of study participation. The cohorts will be matched using propensity scores based on pretreatment demographic and clinical characteristics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
GLP-1 Receptor Agonist Cohort:
Laparoscopic Sleeve Gastrectomy Cohort:
Exclusion Criteria:
Both Cohorts:
GLP-1 Receptor Agonist Cohort:
Laparoscopic Sleeve Gastrectomy Cohort:
Adults aged 18 years or older starting a GLP-1 receptor agonist, such as liraglutide or semaglutide, for weight management as part of routine clinical care. Participants will be followed prospectively for 24 months, with assessments at baseline and months 1, 3, 6, 12, and 24. Weight changes, medication use, treatment adherence, adverse events, and treatment discontinuation will be recorded. Medication selection and dosing will be determined by the treating clinician independently of study participation.
Drug: GLP-1 Receptor Agonist Therapy
Adults who underwent primary laparoscopic sleeve gastrectomy for obesity at the same center between January 1, 2020, and January 1, 2026, and were aged 18 years or older at surgery. Existing medical records will be reviewed retrospectively for baseline characteristics, postoperative weight measurements through 24 months, and surgical complications. This cohort will be matched with the GLP-1 receptor agonist cohort using propensity scores based on pretreatment characteristics. Surgery was performed as part of routine clinical care independently of this study.
Procedure: Laparoscopic Sleeve Gastrectomy
GLP-1 receptor agonists, such as liraglutide or semaglutide, prescribed for weight management as part of routine clinical care. Medication selection, dose escalation, dose adjustment, and treatment discontinuation are determined by the treating clinician and are not assigned by the study protocol. Medication use, weight changes, treatment adherence, and adverse events will be recorded during 24 months of prospective follow-up.
Also known as: Glucagon-Like Peptide-1 Receptor Agonist Therapy
Primary laparoscopic sleeve gastrectomy performed for obesity as part of routine clinical care between January 1, 2020, and January 1, 2026. The procedure involves removing a large portion of the stomach to create a narrow, sleeve-shaped stomach. Existing medical records will be reviewed retrospectively to assess weight changes and surgical complications through 24 months after surgery.
This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.
Percentage of Total Body Weight Loss at 24 Months
Percentage of total body weight loss (%TWL), calculated as \[(baseline body weight - body weight at 24 months) / baseline body weight\] × 100. Baseline is the date of GLP-1 receptor agonist treatment initiation or sleeve gastrectomy. The outcome will be compared between the propensity score-matched treatment cohorts.
Time frame: 24 months after GLP-1 receptor agonist treatment initiation or sleeve gastrectomy.
Percentage of Total Body Weight Loss at Earlier Follow-Up Visits
Percentage of total body weight loss (%TWL), calculated as \[(baseline body weight - follow-up body weight) / baseline body weight\] × 100, compared between the treatment cohorts.
Time frame: At 1, 3, 6, and 12 months after treatment initiation.
Change in Body Weight
Change in body weight from baseline, measured in kilograms, compared between the treatment cohorts.
Time frame: Baseline to months 1, 3, 6, 12, and 24.
Change in Body Mass Index
Change in body mass index (BMI) from baseline, calculated as body weight in kilograms divided by height in meters squared, compared between the treatment cohorts.
Time frame: Baseline to months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 5% Total Body Weight Loss
Percentage of participants losing at least 5% of their baseline body weight, compared between the treatment cohorts.
Time frame: At months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 10% Total Body Weight Loss
Percentage of participants losing at least 10% of their baseline body weight, compared between the treatment cohorts.
Time frame: At months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 15% Total Body Weight Loss
Percentage of participants losing at least 15% of their baseline body weight, compared between the treatment cohorts.
Time frame: At months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 20% Total Body Weight Loss
Percentage of participants losing at least 20% of their baseline body weight, compared between the treatment cohorts.
Time frame: At months 1, 3, 6, 12, and 24.
Percentage of Participants Achieving at Least 25% Total Body Weight Loss
Percentage of participants losing at least 25% of their baseline body weight, compared between the treatment cohorts.
Time frame: At months 1, 3, 6, 12, and 24.
Percentage of Participants Experiencing Any Adverse Event During GLP-1 Therapy
Percentage of participants in the GLP-1 receptor agonist cohort experiencing at least one adverse event. Event type, onset, severity, and suspected relationship to medication will be recorded.
Time frame: From the first medication dose through 24 months.
Percentage of Participants Experiencing Gastrointestinal Adverse Events During GLP-1 Therapy
Percentage of participants in the GLP-1 receptor agonist cohort experiencing gastrointestinal adverse events, including nausea, vomiting, diarrhea, constipation, abdominal pain, or reflux/dyspepsia.
Time frame: From the first medication dose through 24 months.
Percentage of Participants Experiencing Serious Adverse Events During GLP-1 Therapy
Percentage of participants in the GLP-1 receptor agonist cohort experiencing an adverse event resulting in death, a life-threatening condition, inpatient hospitalization or prolonged hospitalization, persistent or significant disability, a congenital anomaly, or another medically important event.
Time frame: From the first medication dose through 24 months.
Percentage of Participants Requiring GLP-1 Dose Reduction Due to Adverse Events
Percentage of participants in the GLP-1 receptor agonist cohort whose medication dose is reduced because of an adverse event.
Time frame: From treatment initiation through 24 months.
Percentage of Participants Permanently Discontinuing GLP-1 Therapy Due to Adverse Events
Percentage of participants in the GLP-1 receptor agonist cohort who permanently discontinue medication because of an adverse event.
Time frame: From treatment initiation through 24 months.
Percentage of Participants Permanently Discontinuing GLP-1 Therapy for Any Reason
Percentage of participants in the GLP-1 receptor agonist cohort who permanently discontinue medication for any reason. Reasons for discontinuation will be recorded.
Time frame: From treatment initiation through 24 months.
Duration of GLP-1 Treatment Persistence
Time in months from GLP-1 receptor agonist treatment initiation to permanent discontinuation. Participants without permanent discontinuation will be censored at their last known follow-up or the end of the 24-month observation period.
Time frame: From treatment initiation through 24 months.
Improvement or Remission of Obesity-Related Comorbidities
Percentage of participants with improvement or remission of baseline obesity-related comorbidities, including type 2 diabetes, hypertension, and dyslipidemia, assessed separately for each condition using available clinical records, laboratory results, and medication changes.
Time frame: At months 3, 6, 12, and 24.
Percentage of Participants With Emergency Department Visits
Percentage of participants with at least one emergency department visit during follow-up, assessed in each treatment cohort using available records.
Time frame: From treatment initiation through 24 months.
Percentage of Participants With Hospital Admissions
Percentage of participants with at least one hospital admission during follow-up, excluding the index admission for sleeve gastrectomy, assessed in each treatment cohort using available records.
Time frame: From treatment initiation through 24 months.
Percentage of Participants With Early Surgical Complications
Percentage of participants in the sleeve gastrectomy cohort experiencing a complication within 30 days after surgery, including bleeding, staple-line leak, or complications requiring reoperation. Complications will be graded using the Clavien-Dindo classification when sufficient information is available.
Time frame: Within 30 days after sleeve gastrectomy.
Percentage of Participants With Late Surgical Complications
Percentage of participants in the sleeve gastrectomy cohort experiencing complications more than 30 days after surgery, including stenosis, gastroesophageal reflux, nutritional deficiencies, or complications requiring revision surgery, as documented in available records.
Time frame: From postoperative day 31 through 24 months.
Other open studies at Yüzüncü Yıl University, Van
Open a list, then choose Watch this search to get new studies there in a weekly email.
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.
Of 541 non-industry observational studies under Obesity, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 111. This study's planned 24 months is below that.
Counting every sponsor, half of 573 studies reached it within 40 months; a quarter within 19 and three quarters within 110.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yuzuncu Yil University